Page 8 - Nasdaq Prtk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wall Street brokerages expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) to post sales of $27.15 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Paratek Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $27.00 million and the highest estimate coming in at $27.30 million. Paratek Pharmaceuticals reported […]

A number of firms have modified their ratings and price targets on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) recently: 3/31/2022 – Paratek Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 3/18/2022 – Paratek Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to […]

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its price target reduced by equities research analysts at HC Wainwright from $27.00 to $22.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Several other research firms have also recently commented on […]

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25), Fidelity Earnings reports. During the same period in the previous year, the firm earned ($0.49) EPS. Paratek Pharmaceuticals updated its FY 2022 […]

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) went up by 5.39% from its latest closing price compared to the recent 1-year high of $11.23. The company’s stock price has collected -1.96% of loss in the last five trading sessions. Press Release reported 10 hours ago that China’s National Medical